Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
beta-lactamase inhibitors	669	58001-44-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clavulanic acid clavulanate clavulanate potassium clavulante potasium clavulanate potassium salt	A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase. Molecular weight: 199.16 Formula: C8H9NO5 CLOGP: -1.06 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 87.07 ALOGS: 0.23 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clavulanic acid
clavulanate
clavulanate potassium
clavulante potasium
clavulanate potassium salt

A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.

Molecular weight: 199.16
Formula: C8H9NO5
CLOGP: -1.06
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 87.07
ALOGS: 0.23
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	43 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	31.38 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	75 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.22 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.91 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.90 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1	39
kinase-selectivity-class	ACVR2B,AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,TEK,TGFBR1	14
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Aug. 6, 1984	FDA	DR REDDYS LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute generalised exanthematous pustulosis	99.74	15.40	43	10659	13660	90604085
Toxic skin eruption	87.69	15.40	41	10661	15733	90602012
Hepatitis cholestatic	86.59	15.40	34	10668	8527	90609218
Cholestasis	84.68	15.40	53	10649	36246	90581499
Bronchiectasis	74.21	15.40	41	10661	22289	90595456
Drug reaction with eosinophilia and systemic symptoms	67.50	15.40	49	10653	42709	90575036
Jaundice	62.38	15.40	42	10660	32475	90585270
Anaphylactic reaction	61.34	15.40	63	10639	87461	90530284
Mixed liver injury	59.03	15.40	25	10677	7598	90610147
Drug hypersensitivity	55.35	15.40	149	10553	463460	90154285
Toxic epidermal necrolysis	50.70	15.40	37	10665	32491	90585254
Hypothyroidism	50.01	15.40	45	10657	53082	90564663
Cholecystitis chronic	49.89	15.40	24	10678	9802	90607943
Rash scarlatiniform	49.84	15.40	10	10692	204	90617541
Neutropenia	49.07	15.40	92	10610	224812	90392933
Bone erosion	46.18	15.40	43	10659	52978	90564767
Nail dystrophy	44.69	15.40	13	10689	1305	90616440
Acute kidney injury	44.41	15.40	109	10593	320278	90297467
International normalised ratio increased	44.38	15.40	40	10662	47276	90570469
Rash maculo-papular	43.19	15.40	37	10665	40896	90576849
Anaphylactic shock	40.52	15.40	32	10670	31585	90586160
Hepatic cytolysis	39.00	15.40	31	10671	30885	90586860
Hepatocellular injury	38.60	15.40	30	10672	28928	90588817
Axillary pain	37.45	15.40	13	10689	2308	90615437
Pruritus	35.52	15.40	142	10560	541383	90076362
Catheter site haemorrhage	35.10	15.40	14	10688	3654	90614091
Clostridium difficile colitis	34.16	15.40	27	10675	26679	90591066
Eosinophilia	32.59	15.40	27	10675	28506	90589239
Emotional distress	32.43	15.40	30	10672	36632	90581113
Appendicitis	31.84	15.40	18	10684	10213	90607532
Bone marrow eosinophilic leukocyte count increased	30.94	15.40	5	10697	27	90617718
Purpura	30.54	15.40	20	10682	14758	90602987
Cholelithiasis	30.10	15.40	34	10668	52472	90565273
Gamma-glutamyltransferase increased	29.66	15.40	29	10673	37923	90579822
Allergic hepatitis	29.59	15.40	5	10697	37	90617708
Dermatitis exfoliative	29.56	15.40	14	10688	5522	90612223
Hydronephrosis	28.64	15.40	18	10684	12384	90605361
Odynophagia	28.39	15.40	16	10686	9027	90608718
Pemphigus	27.99	15.40	3	10699	326861	90290884
Arthropathy	27.53	15.40	5	10697	366237	90251508
Aspartate aminotransferase increased	27.43	15.40	46	10656	102891	90514854
Blood alkaline phosphatase increased	27.33	15.40	31	10671	48048	90569697
Contraindicated product administered	27.26	15.40	3	10699	320136	90297609
Bronchospasm	26.62	15.40	21	10681	20688	90597057
Alanine aminotransferase increased	26.51	15.40	49	10653	118289	90499456
Peripheral swelling	26.40	15.40	8	10694	413098	90204647
Abdominal discomfort	25.90	15.40	12	10690	477316	90140429
Deep vein thrombosis	25.83	15.40	42	10660	91578	90526167
Glossodynia	25.05	15.40	4	10698	321775	90295970
Hyperchlorhydria	24.27	15.40	9	10693	1932	90615813
Prothrombin level decreased	24.22	15.40	7	10695	687	90617058
Stevens-Johnson syndrome	24.00	15.40	23	10679	29353	90588392
Folate deficiency	23.25	15.40	10	10692	3155	90614590
Hyperleukocytosis	22.52	15.40	7	10695	880	90616865
Agranulocytosis	22.37	15.40	24	10678	34978	90582767
Abdominal pain	22.18	15.40	99	10603	395622	90222123
Cytomegalovirus infection	22.05	15.40	21	10681	26581	90591164
Alopecia	21.81	15.40	16	10686	495055	90122690
Drug interaction	21.81	15.40	77	10625	276376	90341369
Joint swelling	21.24	15.40	17	10685	503283	90114462
Wound	20.98	15.40	5	10697	302975	90314770
Nasopharyngitis	20.92	15.40	11	10691	407093	90210652
Pulmonary embolism	20.79	15.40	47	10655	130773	90486972
Ejection fraction decreased	20.40	15.40	20	10682	26233	90591512
Hypokalaemia	19.62	15.40	46	10656	131070	90486675
Chromaturia	19.54	15.40	17	10685	19170	90598575
Linear IgA disease	19.43	15.40	8	10694	2266	90615479
Thrombocytopenia	18.99	15.40	61	10641	208664	90409081
Product use in unapproved indication	18.94	15.40	8	10694	336228	90281517
Constipation	18.70	15.40	74	10628	280321	90337424
Meningitis aseptic	18.64	15.40	11	10691	6762	90610983
Panic attack	18.49	15.40	19	10683	26346	90591399
Hepatitis acute	18.37	15.40	13	10689	10874	90606871
Pseudomembranous colitis	18.29	15.40	9	10693	3859	90613886
Red blood cell sedimentation rate abnormal	17.99	15.40	18	10684	24186	90593559
Exposed bone in jaw	17.49	15.40	8	10694	2918	90614827
Anaemia	17.36	15.40	85	10617	352717	90265028
Febrile bone marrow aplasia	17.30	15.40	12	10690	9726	90608019
Neuropathy peripheral	17.26	15.40	45	10657	136925	90480820
Strawberry tongue	17.23	15.40	3	10699	27	90617718
Maternal exposure during pregnancy	16.69	15.40	11	10691	360052	90257693
Chondroma	16.68	15.40	3	10699	33	90617712
Blood bilirubin increased	16.64	15.40	23	10679	43447	90574298
Swelling	16.64	15.40	15	10687	419043	90198702
Veillonella infection	16.52	15.40	3	10699	35	90617710
Loss of personal independence in daily activities	16.42	15.40	44	10658	136061	90481684
Dementia	16.38	15.40	17	10685	23844	90593901
Off label use	16.29	15.40	71	10631	1102181	89515564
Pyroglutamic acidosis	16.24	15.40	6	10696	1274	90616471
Osteolysis	16.01	15.40	8	10694	3542	90614203
Sepsis	15.85	15.40	52	10650	179762	90437983
Eosinophilic myocarditis	15.70	15.40	5	10697	680	90617065
Erythema	15.68	15.40	61	10641	229185	90388560
Dialysis	15.67	15.40	12	10690	11317	90606428
Blood creatinine increased	15.63	15.40	36	10666	101350	90516395

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	144.39	16.41	77	8260	23601	42589397
Cholestasis	136.07	16.41	83	8254	32796	42580202
Jaundice	89.03	16.41	65	8272	34524	42578474
Hepatitis cholestatic	83.44	16.41	40	8297	9784	42603214
Spinal muscular atrophy	68.60	16.41	16	8321	400	42612598
Motor neurone disease	63.90	16.41	16	8321	543	42612455
Hepatic cytolysis	61.37	16.41	47	8290	26797	42586201
Stoma closure	56.94	16.41	13	8324	295	42612703
Anaphylactic shock	55.57	16.41	42	8295	23475	42589523
Pneumococcal sepsis	52.83	16.41	17	8320	1438	42611560
Purpura	51.69	16.41	31	8306	11848	42601150
Ischaemic cerebral infarction	50.80	16.41	17	8320	1626	42611372
Lymphadenectomy	50.62	16.41	13	8324	489	42612509
Bronchial disorder	49.40	16.41	16	8321	1382	42611616
Lower respiratory tract infection bacterial	49.12	16.41	13	8324	551	42612447
Urethral valves	48.16	16.41	11	8326	250	42612748
Increased bronchial secretion	41.30	16.41	16	8321	2330	42610668
Rash maculo-papular	40.46	16.41	43	8294	37460	42575538
Drug reaction with eosinophilia and systemic symptoms	39.76	16.41	45	8292	42030	42570968
Anaphylactic reaction	39.18	16.41	45	8292	42698	42570300
Toxic epidermal necrolysis	38.72	16.41	36	8301	26714	42586284
Disease complication	37.14	16.41	16	8321	3054	42609944
Scoliosis	36.86	16.41	16	8321	3110	42609888
Sputum increased	36.68	16.41	16	8321	3147	42609851
Off label use	36.43	16.41	43	8294	638292	41974706
Hepatitis	36.20	16.41	35	8302	27265	42585733
Toxic skin eruption	35.74	16.41	26	8311	13704	42599294
Demyelination	35.00	16.41	16	8321	3513	42609485
Jaundice cholestatic	34.58	16.41	18	8319	5235	42607763
Resuscitation	34.10	16.41	13	8324	1812	42611186
Respiratory tract infection bacterial	33.53	16.41	13	8324	1896	42611102
Chest X-ray abnormal	31.27	16.41	16	8321	4492	42608506
Stevens-Johnson syndrome	30.47	16.41	29	8308	22149	42590849
Metabolic disorder	30.36	16.41	16	8321	4772	42608226
Motor dysfunction	29.70	16.41	19	8318	8127	42604871
Eosinophilia	29.08	16.41	34	8303	32865	42580133
Circulatory collapse	28.91	16.41	29	8308	23607	42589391
Blood alkaline phosphatase increased	28.50	16.41	34	8303	33563	42579435
Blood bilirubin increased	28.29	16.41	38	8299	42214	42570784
Brain injury	28.27	16.41	18	8319	7637	42605361
Drug ineffective	27.58	16.41	51	8286	630146	41982852
Cerebral ischaemia	27.30	16.41	17	8320	6942	42606056
Inflammation	26.67	16.41	33	8304	33814	42579184
Chromaturia	26.04	16.41	23	8314	15966	42597032
Lung consolidation	25.41	16.41	16	8321	6661	42606337
Intestinal ischaemia	24.94	16.41	18	8319	9370	42603628
Mechanical ventilation	24.73	16.41	11	8326	2266	42610732
Lung infiltration	24.55	16.41	21	8316	13968	42599030
Muscle atrophy	24.45	16.41	17	8320	8344	42604654
Pruritus	23.78	16.41	86	8251	188685	42424313
Liver function test abnormal	23.02	16.41	30	8307	32361	42580637
Dermatitis exfoliative	22.39	16.41	15	8322	6932	42606066
Atelectasis	22.30	16.41	23	8314	19338	42593660
Endotracheal intubation	22.17	16.41	12	8325	3773	42609225
Kounis syndrome	20.63	16.41	11	8326	3357	42609641
Alanine aminotransferase increased	20.44	16.41	50	8287	88356	42524642
Mixed liver injury	20.30	16.41	12	8325	4462	42608536
Meningitis aseptic	20.28	16.41	12	8325	4470	42608528
Pyrexia	20.27	16.41	139	8198	393903	42219095
Bronchospasm	19.92	16.41	18	8319	12867	42600131
Gamma-glutamyltransferase increased	19.90	16.41	28	8309	32469	42580529
Injury	19.61	16.41	23	8314	22293	42590705
Aspartate aminotransferase increased	19.31	16.41	45	8292	77118	42535880
Death	18.94	16.41	40	8297	471145	42141853
Vascular purpura	18.85	16.41	9	8328	2177	42610821
Secretion discharge	18.83	16.41	14	8323	7621	42605377
Atrophic glossitis	18.46	16.41	3	8334	9	42612989
Toxicity to various agents	18.44	16.41	11	8326	229125	42383873
Product dose omission issue	18.15	16.41	4	8333	154361	42458637
Aminoaciduria	17.92	16.41	5	8332	259	42612739
Erythema	17.63	16.41	54	8283	108739	42504259
Urticaria	17.25	16.41	42	8295	73994	42539004
Face oedema	17.14	16.41	17	8320	13649	42599349
Tachypnoea	16.87	16.41	21	8316	21641	42591357

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cholestasis	220.22	14.41	130	16132	64388	110508649
Hepatocellular injury	180.59	14.41	105	16157	50537	110522500
Hepatitis cholestatic	150.59	14.41	66	16196	17500	110555537
Jaundice	143.33	14.41	96	16166	59140	110513897
Toxic skin eruption	105.94	14.41	60	16202	27455	110545582
Toxic epidermal necrolysis	89.50	14.41	71	16191	56656	110516381
Hepatic cytolysis	89.22	14.41	70	16192	54983	110518054
Anaphylactic reaction	88.28	14.41	96	16166	114204	110458833
Drug reaction with eosinophilia and systemic symptoms	87.32	14.41	82	16180	82013	110491024
Anaphylactic shock	84.52	14.41	66	16196	51480	110521557
Acute generalised exanthematous pustulosis	82.75	14.41	47	16215	21617	110551420
Purpura	75.01	14.41	46	16216	24342	110548695
Spinal muscular atrophy	72.72	14.41	16	16246	411	110572626
Mixed liver injury	71.14	14.41	35	16227	12044	110560993
Rash maculo-papular	65.59	14.41	67	16195	74155	110498882
Motor neurone disease	64.32	14.41	16	16246	708	110572329
Stoma closure	56.58	14.41	13	16249	408	110572629
Blood alkaline phosphatase increased	55.48	14.41	60	16202	70875	110502162
Rash scarlatiniform	52.88	14.41	12	16250	356	110572681
Eosinophilia	50.64	14.41	52	16210	57884	110515153
Pneumococcal sepsis	50.59	14.41	17	16245	2195	110570842
Chromaturia	49	14.41	38	16224	29322	110543715
Gamma-glutamyltransferase increased	48.19	14.41	52	16210	61257	110511780
Aspartate aminotransferase increased	47.85	14.41	85	16177	159851	110413186
Clostridium difficile colitis	47.05	14.41	44	16218	43734	110529303
Alanine aminotransferase increased	46.64	14.41	91	16171	183682	110389355
Jaundice cholestatic	46.06	14.41	28	16234	14580	110558457
Lower respiratory tract infection bacterial	44.37	14.41	13	16249	1072	110571965
Infusion related reaction	44.35	14.41	3	16259	381159	110191878
Lymphadenectomy	44.01	14.41	14	16248	1522	110571515
Bronchial disorder	43.11	14.41	16	16246	2760	110570277
Pruritus	42.80	14.41	184	16078	581376	109991661
Nail dystrophy	42.78	14.41	13	16249	1215	110571822
Stevens-Johnson syndrome	42.63	14.41	43	16219	46858	110526179
Ischaemic cerebral infarction	42.19	14.41	16	16246	2929	110570108
Dermatitis exfoliative	41.67	14.41	24	16238	11323	110561714
Respiratory tract infection bacterial	41.51	14.41	15	16247	2401	110570636
Sputum increased	40.99	14.41	19	16243	5732	110567305
International normalised ratio increased	39.65	14.41	56	16206	86716	110486321
Increased bronchial secretion	37.65	14.41	16	16246	3932	110569105
Peripheral swelling	37.53	14.41	7	16255	404027	110169010
Meningitis aseptic	36.58	14.41	21	16241	9849	110563188
Blood bilirubin increased	36.15	14.41	50	16212	75922	110497115
Bronchospasm	35.63	14.41	32	16230	30207	110542830
Off label use	34.44	14.41	110	16152	1500075	109072962
Nasopharyngitis	34.22	14.41	8	16254	394353	110178684
Axillary pain	33.30	14.41	13	16249	2573	110570464
Drug hypersensitivity	32.85	14.41	143	16119	453947	110119090
Rash morbilliform	32.39	14.41	18	16244	7933	110565104
Acute kidney injury	32.35	14.41	181	16081	635249	109937788
Pyrexia	32.22	14.41	234	16028	898031	109675006
Resuscitation	31.71	14.41	13	16249	2920	110570117
Disease complication	31.70	14.41	16	16246	5811	110567226
Kounis syndrome	31.45	14.41	16	16246	5909	110567128
Hepatitis	29.71	14.41	50	16212	90004	110483033
Bone marrow eosinophilic leukocyte count increased	29.69	14.41	5	16257	28	110573009
Demyelination	29.54	14.41	18	16244	9411	110563626
Drug ineffective	29.25	14.41	120	16142	1520420	109052617
Chest X-ray abnormal	28.65	14.41	17	16245	8470	110564567
Neutropenia	28.65	14.41	120	16142	374500	110198537
Brain injury	28.23	14.41	20	16242	13456	110559581
Lung consolidation	27.80	14.41	18	16244	10458	110562579
Metabolic disorder	27.74	14.41	18	16244	10492	110562545
Allergic hepatitis	27.24	14.41	5	16257	49	110572988
Cholecystitis chronic	26.89	14.41	17	16245	9483	110563554
Thrombocytopenia	26.86	14.41	112	16150	348773	110224264
Arthropathy	26.65	14.41	5	16257	287517	110285520
Hepatitis acute	26.44	14.41	22	16240	18744	110554293
Circulatory collapse	26.24	14.41	32	16230	42961	110530076
Catheter site haemorrhage	25.85	14.41	14	16248	5866	110567171
Scoliosis	25.65	14.41	16	16246	8717	110564320
Face oedema	25.62	14.41	28	16234	33441	110539596
Cerebral ischaemia	25.44	14.41	18	16244	12086	110560951
Atelectasis	25.17	14.41	29	16233	36683	110536354
Intestinal ischaemia	24.97	14.41	20	16242	16159	110556878
Abdominal discomfort	24.10	14.41	14	16248	393844	110179193
Muscle atrophy	23.97	14.41	18	16244	13236	110559801
Mechanical ventilation	23.80	14.41	11	16251	3296	110569741
Contraindicated product administered	23.70	14.41	4	16258	248263	110324774
Tachypnoea	23.52	14.41	29	16233	39366	110533671
Strawberry tongue	23.24	14.41	4	16258	26	110573011
Lung infiltration	23.15	14.41	23	16239	24605	110548432
Joint swelling	22.78	14.41	19	16243	442826	110130211
Vascular purpura	22.42	14.41	11	16251	3760	110569277
Mobility decreased	22.28	14.41	4	16258	237418	110335619
Bronchiectasis	22.01	14.41	27	16235	36466	110536571
Pemphigus	21.52	14.41	3	16259	214567	110358470
Treatment failure	21.47	14.41	7	16255	277227	110295810
Hydronephrosis	20.73	14.41	20	16242	20645	110552392
Faeces pale	20.58	14.41	10	16252	3347	110569690
Emotional distress	20.56	14.41	29	16233	44818	110528219
Maternal exposure during pregnancy	20.52	14.41	6	16256	254877	110318160
Therapeutic product effect incomplete	20.51	14.41	4	16258	223801	110349236
Weight increased	20.38	14.41	19	16243	419625	110153412
Cholestatic liver injury	20.38	14.41	13	16249	7363	110565674
Glossodynia	20.27	14.41	4	16258	222000	110351037
Dehydration	20.16	14.41	88	16174	279423	110293614
Agranulocytosis	19.98	14.41	34	16228	61726	110511311
Endotracheal intubation	19.94	14.41	12	16250	6132	110566905
Death	19.89	14.41	46	16216	698823	109874214
Wound	19.85	14.41	5	16257	234432	110338605
Deep vein thrombosis	19.70	14.41	55	16207	139832	110433205
Intentional product use issue	19.66	14.41	6	16256	247900	110325137
Febrile bone marrow aplasia	19.63	14.41	18	16244	17447	110555590
Pseudomembranous colitis	19.51	14.41	12	16250	6379	110566658
Type I hypersensitivity	19.50	14.41	12	16250	6381	110566656
Cholelithiasis	19.33	14.41	34	16228	63388	110509649
Headache	19.26	14.41	66	16196	882311	109690726
Therapeutic product effect decreased	19.22	14.41	6	16256	244310	110328727
Product dose omission issue	18.89	14.41	12	16250	321770	110251267
Odynophagia	18.77	14.41	16	16246	14085	110558952
Cholangitis	18.68	14.41	17	16245	16318	110556719
Renal failure	18.42	14.41	74	16188	226500	110346537
Erythema	18.23	14.41	88	16174	291359	110281678
Hyperchlorhydria	18.10	14.41	8	16254	2161	110570876
Drug interaction	17.69	14.41	130	16132	500053	110072984
Product use in unapproved indication	17.64	14.41	24	16238	447353	110125684
Aminoaciduria	17.58	14.41	5	16257	371	110572666
Pulmonary hilum mass	17.32	14.41	5	16257	391	110572646
Hypothyroidism	17.15	14.41	35	16227	72864	110500173
Transaminases increased	16.81	14.41	32	16230	63358	110509679
Rash	16.59	14.41	189	16073	820775	109752262
Liver function test abnormal	16.10	14.41	33	16229	68917	110504120
Alopecia	16.02	14.41	18	16244	364735	110208302
Hyperbilirubinaemia	15.82	14.41	21	16241	30650	110542387
Lower respiratory tract infection	15.80	14.41	8	16254	243098	110329939
Bone erosion	15.63	14.41	26	16236	46345	110526692
Appendicitis	15.48	14.41	20	16242	28444	110544593
Diarrhoea	15.44	14.41	244	16018	1139261	109433776
Atrophic glossitis	15.42	14.41	3	16259	41	110572996
Linear IgA disease	15.36	14.41	9	16253	4380	110568657
Folate deficiency	15.27	14.41	9	16253	4429	110568608
Rheumatoid arthritis	15.22	14.41	13	16249	299600	110273437
Infective exacerbation of chronic obstructive airways disease	15.16	14.41	8	16254	3182	110569855
Veillonella infection	14.98	14.41	3	16259	48	110572989
Hypertension	14.97	14.41	33	16229	510051	110062986
Respiratory distress	14.96	14.41	32	16230	68842	110504195
Hyperthermia	14.91	14.41	17	16245	21255	110551782
Blood pressure increased	14.67	14.41	10	16252	258363	110314674
Injection site pain	14.67	14.41	4	16258	177918	110395119
Motor dysfunction	14.62	14.41	18	16244	24388	110548649
Injury	14.49	14.41	58	16204	177207	110395830

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000000202	beta Lactamase Inhibitors
FDA EPC	N0000175930	beta Lactamase Inhibitor
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D065093	beta-Lactamase Inhibitors
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:33231	antitubercular agent
CHEBI has role	CHEBI:33281	antimicrobial agent
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35620	vasodilator agent
CHEBI has role	CHEBI:35625	EC 3.5.2.6 (β-lactamase) inhibitor
CHEBI has role	CHEBI:36047	antibacterial drug
CHEBI has role	CHEBI:49201	anti-ulcer drug
CHEBI has role	CHEBI:65023	anti-asthmatic agent
CHEBI has role	CHEBI:74518	anti-obesity agent
CHEBI has role	CHEBI:76969	bacterial metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Pneumonia due to Klebsiella pneumoniae	indication	64479007
Urinary tract infectious disease	indication	68566005
Haemophilus influenzae pneumonia	indication	70036007
Infection due to Escherichia coli	indication	71057007
Rhinoscleroma	indication	72409005	DOID:11336
Acute bacterial sinusitis	indication	75498004
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Pneumococcal pneumonia	indication	233607000
Escherichia coli urinary tract infection	indication	301011002
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infection due to Staphylococcus aureus	indication	406602003
Osteomyelitis due to Staphylococcus aureus	indication	428783003
Pneumonia due to Staphylococcus aureus	indication	441658007
Sepsis due to Staphylococcus aureus	indication	448417001
Sepsis due to Pseudomonas	indication	448813005
Moraxella Catarrhalis Acute Otitis Media	indication	703469002
Bacteroides Endometritis	indication
Pneumococcal Acute Otitis Media	indication
Haemophilus Parainfluenzae Pneumonia	indication
Pseudomonas Aeruginosa Urinary Tract Infection	indication
Klebsiella Endometritis	indication
Klebsiella Pneumoniae Peritonitis	indication
Moraxella Catarrhalis Pneumonia	indication
Staphylococcus Aureus Joint Infection	indication
Staphylococcus Aureus Urinary Tract Infection	indication
E. Coli Peritonitis	indication
Enterobacter Endometritis	indication
Bacteroides Peritonitis	indication
Serratia Urinary Tract Infection	indication
Citrobacter Urinary Tract Infection	indication
Staphylococcus Endometritis	indication
E. Coli Endometritis	indication
Acute otitis media	off-label use	3110003
Pyrexia of unknown origin	off-label use	7520000
Chronic purulent otitis media	off-label use	38394007	DOID:14247
Cholangitis	off-label use	82403002	DOID:9446
Human bite - wound	off-label use	262555007
Chancroid	off-label use	266143009	DOID:13778
Diverticulitis of gastrointestinal tract	off-label use	271366000
Dog bite - wound	off-label use	283734005
Cat bite - wound	off-label use	283782004
Acute exacerbation of chronic bronchitis	off-label use	425748003
Diabetic Foot Infection	off-label use
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis	off-label use
Obstruction of bile duct	contraindication	30144000
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Infectious mononucleosis	contraindication	271558008	DOID:8568
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Urinary tract infections caused by Escherichia coli	Indication
Dogs	Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus	Indication
Dogs	Skin and soft tissue infections caused by Staphylococcus spp	Indication
Dogs	Skin and soft tissue infections caused by Streptococcus spp	Indication
Dogs	Skin and soft tissue infections caused by Escherichia coli	Indication
Dogs	Skin and soft tissue infections caused by Pasteurella spp	Indication
Cats	Urinary tract infections caused by Escherichia coli	Indication
Cats	Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus	Indication
Cats	Skin and soft tissue infections caused by Staphylococcus spp	Indication
Cats	Skin and soft tissue infections caused by Streptococcus spp	Indication
Cats	Skin and soft tissue infections caused by Escherichia coli	Indication
Cats	Skin and soft tissue infections caused by Pasteurella spp	Indication
Cats	Periodontal infections due aerobic and anaerobic bacteria	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
CLAVAMOX CHEWABLE Tablets, CLAVAMOX tablets	Zoetis Inc.	2
Clavamox Drops	Zoetis Inc.	2
Clavacillin	Dechra Veterinary Products LLC	2
Amoxicillin and Clavulanate Potassium for Oral Suspension	Dechra Veterinary Products LLC	2
Amoxicillin and Clavulanate Potassium Tablets	Cronus Pharma Specialities India Private Limited	2
Amoxicillin and Clavulanate Potassium for Oral Suspension	Cronus Pharma Specialities India Private Limited	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.07	acidic
pKa2	13.53	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-lactamase TEM	Enzyme	BLAT_ECOLX	INHIBITOR	IC50	10.19	WOMBAT-PK	CHEMBL
Beta-lactamase	Enzyme	AMPC_ECOLI		IC50	7.82	CHEMBL
Beta-lactamase	Enzyme	Q59401_ENTCL		IC50	4	CHEMBL
Beta-lactamase SHV-1	Enzyme	BLA1_ECOLX		IC50	7.55	CHEMBL
Beta-lactamase	Enzyme	AMPC_ENTCL		Kd	6.40	CHEMBL
Beta-lactamase OXA-1	Enzyme	BLO1_ECOLX		IC50	5.49	CHEMBL
Beta-lactamase	Enzyme	AMPC_PSEAE		IC50	6.10	CHEMBL
Beta-lactamase	Enzyme	A4KCT8_9ENTR		IC50	8.05	CHEMBL
Beta-lactamase	Enzyme	A1E3K9_ECOLX		IC50	7.15	CHEMBL
Beta-lactamase	Enzyme	A8RR46_BACCS		IC50	7.07	CHEMBL
Carbapenem-hydrolizing beta-lactamase SFC-1	Enzyme	Q6JP75_SERFO		IC50	4.14	CHEMBL
Carbepenem-hydrolyzing beta-lactamase KPC	Enzyme	BLKPC_KLEPN		Ki	4.96	CHEMBL
Beta-lactamase	Enzyme	A2RP81_CITFR		IC50	7.17	CHEMBL
Beta-lactamase	Enzyme	Q9EXV5_ECOLX		IC50	8.05	CHEMBL
Beta-lactamase SHV-1	Enzyme	BLA1_KLEPN		IC50	6.77	CHEMBL
Beta-lactamase	Enzyme	Q6GWS8_ECOLX		IC50	5.07	CHEMBL
Beta-lactamase GES-13	Enzyme	D1MIX9_PSEAI		IC50	7	CHEMBL
Beta-lactamase	Enzyme	A0ZX81_KLEPN		IC50	5.76	CHEMBL
Beta-lactamase	Enzyme	Q4TVR4_KLEPN		IC50	7.70	CHEMBL
Class D beta-lactamase	Enzyme	Q50H31_BRAPL		IC50	5.70	CHEMBL
Beta-lactamase	Enzyme	Q2XPY6_SALET		IC50	8	CHEMBL
Beta-lactamase SHV-5	Enzyme	BLA5_KLEPN		Ki	4.60	CHEMBL
Beta-lactamase	Enzyme	D2SSQ3_PSEAI		IC50	7	CHEMBL
Beta-lactamase	Enzyme	Q3SAW3_PSEAI		IC50	7	CHEMBL
Beta-lactamase	Enzyme	BLAC_STAAU		MPC	8.72	WOMBAT-PK
Beta-lactamase	Enzyme	Q670S6_PSELU		IC50	7.44	CHEMBL

External reference:

ID	Source
N0000005804	NUI
D02370	KEGG_DRUG
61177-45-5	SECONDARY_CAS_RN
21216	RXNORM
C0055860	UMLSCUI
CHEBI:48947	CHEBI
J01	PDB_CHEM_ID
CHEMBL777	ChEMBL_ID
DB00766	DRUGBANK_ID
CHEMBL1003	ChEMBL_ID
D019818	MESH_DESCRIPTOR_UI
5280980	PUBCHEM_CID
11128	IUPHAR_LIGAND_ID
4948	INN_ID
23521W1S24	UNII
4463	MMSL
d04405	MMSL
002808	NDDF
002809	NDDF
395938000	SNOMEDCT_US
395939008	SNOMEDCT_US
412318009	SNOMEDCT_US
4018406	VANDF
4019680	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2274	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2274	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2275	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2275	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2277	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2277	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2279	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2279	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-8675	POWDER, FOR SUSPENSION	42.90 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9249	TABLET	125 mg	ORAL	ANDA	28 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9249	TABLET	125 mg	ORAL	ANDA	28 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9853	SUSPENSION	42.90 mg	ORAL	ANDA	25 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9981	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	28 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9982	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	28 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-1831	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-1852	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-1874	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	3	0781-1943	TABLET, MULTILAYER, EXTENDED RELEASE	62.50 mg	ORAL	ANDA	25 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-6102	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-6104	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-6139	SUSPENSION	42.90 mg	ORAL	ANDA	25 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	10544-931	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	10544-951	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
AMOXICILLIN AND CLAVULANATE POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	2	16590-019	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
AMOXICILLIN AND CLAVULANATE POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	2	16590-020	TABLET, FILM COATED	125 mg	ORAL	ANDA	15 sections
Amoxicillin and Clavulanate Potassium	Human Prescription Drug Label	2	16714-292	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	Human Prescription Drug Label	2	16714-293	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	Human Prescription Drug Label	2	16714-294	POWDER, FOR SUSPENSION	42.90 mg	ORAL	ANDA	25 sections
Amoxicillin and Clavulanate Potassium	Human Prescription Drug Label	2	16714-295	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	Human Prescription Drug Label	2	16714-296	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections

Ask DrugCentral

Try a sample question

clavulanic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: